IL6 and Sepsis: Alongside these findings, the trial of the TNF-α mAb afelimomab, known as the RAMESES study, provides a nuanced perspective by demonstrating a modest but significant reduction in 28-day mortality in sepsis patients with IL-6 serum levels higher than 1000 pg/mL [45].